- Home
- ISRL vs ASRT Comparison
ISRL vs ASRT Comparison
Compare ISRL & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISRL
- ASRT
- Stock Information
- Founded
- ISRL 2021
- ASRT 1995
- Country
- ISRL United States
- ASRT United States
- Employees
- ISRL N/A
- ASRT N/A
- Industry
- ISRL Blank Checks
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- ISRL Finance
- ASRT Health Care
- Exchange
- ISRL Nasdaq
- ASRT Nasdaq
- Market Cap
- ISRL 80.2M
- ASRT 79.1M
- IPO Year
- ISRL 2023
- ASRT 1997
- Fundamental
- Price
- ISRL $12.35
- ASRT $0.88
- Analyst Decision
- ISRL
- ASRT Strong Buy
- Analyst Count
- ISRL 0
- ASRT 1
- Target Price
- ISRL N/A
- ASRT $3.00
- AVG Volume (30 Days)
- ISRL 2.4K
- ASRT 317.9K
- Earning Date
- ISRL 01-01-0001
- ASRT 11-10-2025
- Dividend Yield
- ISRL N/A
- ASRT N/A
- EPS Growth
- ISRL N/A
- ASRT N/A
- EPS
- ISRL 0.14
- ASRT N/A
- Revenue
- ISRL N/A
- ASRT $117,099,000.00
- Revenue This Year
- ISRL N/A
- ASRT N/A
- Revenue Next Year
- ISRL N/A
- ASRT $6.75
- P/E Ratio
- ISRL $93.89
- ASRT N/A
- Revenue Growth
- ISRL N/A
- ASRT N/A
- 52 Week Low
- ISRL $11.14
- ASRT $0.51
- 52 Week High
- ISRL $14.00
- ASRT $1.16
- Technical
- Relative Strength Index (RSI)
- ISRL 46.77
- ASRT 51.89
- Support Level
- ISRL $12.30
- ASRT $0.87
- Resistance Level
- ISRL $13.00
- ASRT $0.93
- Average True Range (ATR)
- ISRL 0.29
- ASRT 0.04
- MACD
- ISRL 0.01
- ASRT -0.01
- Stochastic Oscillator
- ISRL 31.67
- ASRT 8.41
About ISRL Israel Acquisitions Corp
Israel Acquisitions Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.